Louis Chenevert Is The Real Reason For United Technology Corporation’s Success

Louis Chenevert is an entrepreneur and business leader who has achieved plenty in his lifetime. He started from humble beginnings and had to work his way up to where he eventually made it. He was born in Montréal, Québec where he became interested in business at an early age. he learned, early on, that hard work and determination were what helped people to succeed in their life. He decided to go to college and majored in Production Management at the University of Montréal. After this, he was quickly hired on by General Motors at St. Therese, Quebec where he was tasked with managing its assembly line.

 

After working for General Motors for 14 years, Louis Chenevert could feel it was time for a change. He decided to move forward and work in the aerospace industry where he teamed up with Pratt & Whitney, which is a company that is part of the larger United Technologies Corporation. In 1999, Chenevert became President of Pratt & Whitney and began to reconstruct the company from the top to bottom. He ended making Pratt & Whitney a profitable company after it had been suffering with his leadership skills and willingness to explore new technologies.

 

Louis Chenevert ended up catching the attention of United Technologies Corporation and also put together the geared turbofan (GTF) engine in the provess. He became the Chairman of UTC in 2006 and its Director and invested in the GTF engine, which he knew would be a hit in the industry. Today, the GTF engine is huge in its market and has earned UTC plenty of profit. It, literally, put the company back on the map and is now used by over 14 different airlines as well as 70 different aircraft.

 

Louis Chenevert eventually became the CEO of UTC and has received plenty of praise since he took over the role. He loves challenge and saw UTC through some of the roughest times in the United States economy. He is sure that the company’s portfolio of products will help it succeed moving into the future and is glad that he has focused on taking care of the company’s employees. While Louis Chenevert is not the CEO of UTC anymore, he left behind an amazing legacy that continues today.

 

https://www.wingsjournal.com/yachts-rich-famous-louis-chenevert-steve-jobs-johnny-depp

July 11, 2018

Posted In: Business, Businessman, CEO, Entrepreneur, Investment, Investor, Leader

Tags: , , ,

Tony Petrello supports Jan and Dan Duncan Neurological Research Center

Tony Petrello is one of the people who has contributed immensely to the development of a facility that will help in treating the neurological disorders in children. In the history of medical services, there has never been a facility that offers treatment in this area of medication. The main reason this has not been happening is that no facility has ever conducted advanced research on the cause of these conditions. This has been the case for a long to time, but it will no longer be the same with the entry of Tony Petrello in the medical industry as a philanthropist. Being a generous philanthropist, he is committed to supporting projects that will realize the goals set out. In the case of neurological research, he is committed to facilitating the development of the facility until such a time when the main goal that was set out is accomplished.

In aid of development if this facility, he has donated $5 million and has promised to add another $2 million which will also go to the development of the facility. The donations that he is giving will go a long way in ensuring that children born with neurological disorder get the right treatment. Neurological disorders in children end up hurting their entire life since they cannot live like other human beings.

Jan and Dan Duncan Research Center is going to the first facility in the world to conduct research in this field of medicine. Tony Petrello and his wife Cynthia want to see this company succeed by ensuring that all the activities of the center are facilitated. By having sufficient funds to support the research, they hope the set-out goals will be accomplished. Tony and his wife co-chair fundraising committee on behalf of the facility, so far, they have managed to bring $500 million from donations made from all over the world.

The cause that they are supporting will go a long way in supporting children who suffer from neurological disorders, one of them being their daughter. In fact, Tony Petrello realized the problem when he was looking for a medical facility that could cure his daughter. There was no such facility in any part of the world and that is how he realized that he needed to do something to save the situation.

For More info: www.ckwluxe.com/cynthia-petrello-full

July 5, 2018

Posted In: Businessman, Investor

Tags:

Sahm Adrangi Is Taking The Short Side With Proteostasis With Latest Negative Report From Kerrisdale

Sahm Adrangi is a well-known man in the investing world thanks to his many accomplishments as an investor and his success at Kerrisdale Capital. This private investment firm invests in various companies around the world. Today, being able to identify quality companies in the stock market is a challenge, and Sahm Adrangi is standing out where not many can. Kerrisdale has managed to excel and come out on top of the S&P 500 for several successive quarters.

On a normal basis, Kerrisdale Capital puts out reports on various companies in the market, and their latest was quite the negative report against biotech firm Proteostasis. This biotech company is home to Cambridge and has recently been making claims of a new breakthrough in terms of cystic fibrosis. Their new drug in development, PTI-428, is aimed at helping increasing lung performance in patients.

Unfortunately for Proteostasis, Kerrisdale was not impressed with their figures and the data they released, so Sahm Adrangi decided to do a little more digging into the company. Upon even closer examination of the results of the company, their actual test sample was extremely small. So small in fact, PTI-428 was only tested on four patients. This is not nearly enough to make such claims the company has been making, causing their company stock value to go up.

Kerrisdale took quickly to their report to get it out as soon as possible to inform the public and many investors out there of what is really behind this biotech company, Proteostasis. According to Sahm Adrangi, their drug cocktail is most likely an ineffective drug that works better as a placebo. Unfortunately for Proteostasis, the majority of their company value is invested in their product, which means they will lose more than 70% of their company share value when it comes out that PTI-428 is not effective.

As more companies and investors are becoming aware of the nature of this biotech company, their share values continue to drop and will likely push the company off the map in the near future.

http://www.imdb.com/name/nm1444924/

April 19, 2018

Posted In: Business, Business success, Businessman, CEO, Entrepreneur, Investor

Tags: , , , , , , , , ,

Tempus Technologies of Eric Lefkofky Receives $ 80 Million

The name Eric Lefkofsky is trending because of some noble actions of the great inventor and technology geek. Eric is the CEO of Tempus; a technology outfit that has hit the news for months about its efforts to battle cancer by using cutting-edge technologies. He is also a co-founder of the company and a couple of others in the technology field. Eric is so conspicuous because of his liking for disruptive technologies that help enhance service delivery, especially in the health services sector. Eric also co-founded a NASDAQ-listed company by the name Groupon. The list of the tech companies Eric has helped to start or started on his own is long, but one of the most outstanding because of the contribution it has already made in the fight against cancer is Tempus. It is an operating system that uses personalized patient data to develop profiles and analysis of a patient’s cancer status and trends. Physicians have found the technology handy because it helps them make fast decisions about the cancer patients that they interact with; decisions that are often helpful in battling cancer before the condition spread its ominous tentacles too far. Tempus has already networked with many cancer centers in the US. Now it is getting some money for growth.

Tempus Receives More Donor Funding

According to reports by the Chicago Tribune recently, Mr. Eric Lefkofsky’s Tempus Company has just received a cash boost. It will be yet another gesture of support for the work by the young American inventor and technology enthusiast who uses his passion and skills in technology to promoter cancer treatment and handling. Tempus is noted to be an important resource in promoting upcoming technologies that prove to have the potential to change the old order of things, especially in the medical world. According to the Chicago Tribune report, Tempus has received over $ 80 million from what the news source describes as existing and new investors. So far, Tempus, under the umbrella of Groupon has received up to $210 million since it was started in 2015. Tempus breaks the record of companies that have had the most profound impact on humanity barely two years since they were started. The latest funding is a boost to Mr. Eric Lefkofky’s work in battling the cancer menace through technology. To know more about him click here.

His Contributions to Society

Eric Lefkofsky has demonstrated a heart for helping those who have been afflicted by disease and pain. He and his wife formed the Lefkofsky Family Foundation. The Foundation seeks to extend charity assistance to needy communities and individuals around the globe to resolve or mitigate their health concerns. Eric is a respected personality already. He is a trustee of Lurie Children’s Hospital based in Chicago, the Museum of Science among others.

April 3, 2018

Posted In: Businessman, CEO

Tags: